10.1016/j.nutx.2019.100005 6
Learn more Retatrutide Therapy Next-generation triple agonist (GLP-1/GIP/glucagon) showing the highest weight loss yet in clinical trials
Repurposing drugs can reduce the time and cost of development, especially when a drugs pharmacological properties and safety profile have already been established
(More research is needed to fully understand the relationship between semaglutide and joint pain in some patients.) The link between Ozempic and joint pain could be due to the medications effects on GLP-1 receptors, not just in the pancreas and brain, but also possibly in other areas of the body including the joints or tissues surrounding the joints
June 25th, 2024: Research shows increased aspiration pneumonia risk for GLP-1 users during procedures Recent research highlights a significant concern for users of glucagon-like peptide-1 receptor agonists (GLP-1RAs), commonly prescribed for diabetes management
After three decades and more than two hundred papers, there is still no published randomized controlled trial showing efficacy
:max_bytes(150000):strip_icc()/Wegovy-pill-pic-590ed53ed3304ba8b2388f9d78886dae.png)
